An oral dengue drug protected 6 of 10 volunteers. The virus mutated in all of them

About half the world's population is at risk of dengue, and there is no antiviral prophylaxis or treatment for it [s1]. That sentence has been true for decades. A phase 2a trial published in the New England Journal of Medicine on 26 November reports the first controlled human evidence that an oral drug can blunt a dengue infection before it takes hold — and, in the same dataset, the first clear sign of how quickly the virus adapts to it [s1]. The journal's accompanying editorial is titled "Toward a Dengue Pill", which is the right distance to keep [s2].

How the trial was built

Human challenge trials deliberately infect healthy volunteers with a weakened virus under close supervision. This one used a controlled human infection model in which participants received a subcutaneous inoculation of an under-attenuated dengue virus serotype 3 strain, rDEN3Δ30 [s1].

Healthy adults were randomly assigned, double-blind, to oral mosnodenvir once daily at one of three dose levels or to matched placebo [s1]. The doses were a low regimen (40 mg loading dose followed by 10 mg maintenance), a medium regimen (200 mg then 50 mg), and a high regimen (600 mg then 200 mg) [s1]. Loading doses ran for 5 days and maintenance doses for 21 days [s1]. Inoculation happened on the day of the first maintenance dose, designated day 1 [s1].

The primary efficacy endpoint was the DENV-3 RNA load, measured as the log₁₀ area under the concentration-time curve from day 1, immediately before inoculation, through day 29 [s1]. Only the high-dose and placebo groups were compared in the primary analysis [s1]. Safety, pharmacokinetics and virologic and serologic features were followed through day 85 [s1].

Earlier phase 1 work had established that the drug's exposure could be sustained: across maintenance regimens in healthy adults, the mean terminal elimination half-life was 6.7 to 8.7 days, which the investigators read as supporting less frequent dosing [s3]. In the challenge trial, plasma concentrations of mosnodenvir rose from day −5 to day 1 and were maintained through day 21 [s1].

What happened

The proportion of participants with no signs of DENV-3 infection was 0% (0 of 6) on the low dose, 17% (1 of 6) on the medium dose, and 60% (6 of 10) on the high dose, compared with 0% (0 of 7) on placebo [s1].

High-dose mosnodenvir produced a significantly lower DENV-3 RNA load than placebo on the primary endpoint (two-sided P<0.001 by tobit analysis of variance) [s1]. No serious adverse events occurred [s1].

Those are small groups — six, six, ten and seven people. The dose-response pattern is orderly, which lends the result some weight, but a 60% protection figure resting on 10 participants carries wide uncertainty that the point estimate hides.

The finding that complicates it

Among participants with available NS4B sequencing data, emerging amino acid variations in the NS4B region of the rDEN3Δ30 genome were detected in 14 of 14 mosnodenvir recipients and in none of 7 placebo recipients [s1].

Changes concentrated in one region of the viral genome, appearing in every sequenced treated participant and in no untreated one, is the signature of selection pressure: the drug is doing something to the virus, and the virus is changing in response within a single short course [s1].

The trial does not establish that those variants confer clinically meaningful resistance, and it should not be read as saying so [s1]. What it establishes is that the pressure is real and fast. For a drug being developed as daily prophylaxis — taken by healthy people, potentially for long stretches of a transmission season — that is a first-order design question rather than a footnote.

What the model can and cannot show

A controlled human infection model uses a laboratory-attenuated strain, a known inoculum, a known timing, and healthy adult volunteers. Real dengue arrives by mosquito, at an unknown dose, in people of all ages and health states, and in more than one serotype — this trial tested a serotype 3 strain only [s1]. The model is a way of getting a clean efficacy signal early; it is not a substitute for field trials, and this trial makes no claim about severe dengue, hospitalisation or death.

The comparison that matters clinically — does taking this drug reduce symptomatic dengue in a place where dengue circulates — has not been run.

What to watch

Three things. Whether the high-dose regimen's protection holds in a larger challenge cohort or a field study. Whether the NS4B variants seen here affect drug susceptibility when characterised. And whether a prophylactic dosing schedule can be built that keeps exposure high enough to suppress the virus without inviting more of the adaptation the trial just documented.

The trial was funded by the National Institute of Allergy and Infectious Diseases and Johnson & Johnson, and registered as NCT05048875 [s1].

Sources

• [s1] Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model, The New England Journal of Medicine, 26 November 2025. https://doi.org/10.1056/NEJMoa2500179
• [s2] Toward a Dengue Pill, The New England Journal of Medicine, 26 November 2025. https://doi.org/10.1056/NEJMe2515056
• [s3] Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ-1802) in Healthy Adult Participants, Clinical Pharmacology in Drug Development, 15 July 2025. https://doi.org/10.1002/cpdd.1574